- Home
- PAYO vs MNKD Comparison
PAYO vs MNKD Comparison
Compare PAYO & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYO
- MNKD
- Stock Information
- Founded
- PAYO 2005
- MNKD 1991
- Country
- PAYO United States
- MNKD United States
- Employees
- PAYO N/A
- MNKD N/A
- Industry
- PAYO EDP Services
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- PAYO Technology
- MNKD Health Care
- Exchange
- PAYO Nasdaq
- MNKD Nasdaq
- Market Cap
- PAYO 2.1B
- MNKD 1.7B
- IPO Year
- PAYO N/A
- MNKD 2004
- Fundamental
- Price
- PAYO $5.25
- MNKD $5.80
- Analyst Decision
- PAYO Strong Buy
- MNKD Strong Buy
- Analyst Count
- PAYO 8
- MNKD 5
- Target Price
- PAYO $10.06
- MNKD $10.80
- AVG Volume (30 Days)
- PAYO 2.7M
- MNKD 5.0M
- Earning Date
- PAYO 11-05-2025
- MNKD 11-05-2025
- Dividend Yield
- PAYO N/A
- MNKD N/A
- EPS Growth
- PAYO N/A
- MNKD 23.47
- EPS
- PAYO 0.18
- MNKD 0.10
- Revenue
- PAYO $1,039,820,000.00
- MNKD $313,787,000.00
- Revenue This Year
- PAYO $9.64
- MNKD $14.78
- Revenue Next Year
- PAYO $7.37
- MNKD $19.36
- P/E Ratio
- PAYO $29.58
- MNKD $61.91
- Revenue Growth
- PAYO 10.58
- MNKD 17.43
- 52 Week Low
- PAYO $4.92
- MNKD $3.38
- 52 Week High
- PAYO $11.29
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- PAYO 28.61
- MNKD 59.01
- Support Level
- PAYO $4.92
- MNKD $5.42
- Resistance Level
- PAYO $5.87
- MNKD $6.24
- Average True Range (ATR)
- PAYO 0.20
- MNKD 0.27
- MACD
- PAYO -0.04
- MNKD 0.03
- Stochastic Oscillator
- PAYO 25.19
- MNKD 57.83
About PAYO Payoneer Global Inc.
Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.